Cargando…

Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices

Antibody–drug conjugates (ADCs) are a new class of biotherapeutics, consisting of a cytotoxic payload covalently bound to an antibody by a linker. Ligand-binding assay (LBA) and liquid chromatography-mass spectrometry (LC-MS) are the favored techniques for the analysis of ADCs in biomatrices. The go...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Qiuping, Gong, Likun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572530/ https://www.ncbi.nlm.nih.gov/pubmed/36234836 http://dx.doi.org/10.3390/molecules27196299

Ejemplares similares

Selection of appropriate biomatrices for studies of chronic stress in animals: a review
por: Ataallahi, Mohammad, et al.
Publicado: (2022)

Epithelial cells as alternative human biomatrices for comet assay
por: Rojas, Emilio, et al.
Publicado: (2014)

Biodegradable biomatrices and bridging the injured spinal cord: the corticospinal tract as a proof of principle
por: Joosten, Elbert A. J.
Publicado: (2012)

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

ZnO Interactions with Biomatrices: Effect of Particle Size on ZnO-Protein Corona
por: Yu, Jin, et al.
Publicado: (2017)

Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates
por: Zhu, Xiaoyu, et al.
Publicado: (2020)

Fractone Stem Cell Niche Components Provide Intuitive Clues in the Design of New Therapeutic Procedures/Biomatrices for Neural Repair
por: Melrose, James
Publicado: (2022)

In Vivo Isolation and Characterization of Stem Cells with Diverse Phenotypes Using Growth Factor Impregnated Biomatrices
por: Grimaldi, Annalisa, et al.
Publicado: (2008)

Interdental Papillary Reconstruction by Microtunnelling Technique Using Autologous Biomatrices—A Randomised Controlled Clinical Trial
por: Gadi, Sindhura, et al.
Publicado: (2022)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
por: Wang, Yu-Jie, et al.
Publicado: (2017)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
por: Mark, Cynthia, et al.
Publicado: (2023)

ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
por: Mou, Si, et al.
Publicado: (2018)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Antimicrobial Chitosan Conjugates: Current Synthetic Strategies and Potential Applications
por: Qin, Yukun, et al.
Publicado: (2020)

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
por: Kim, Jung Hoon, et al.
Publicado: (2022)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression
por: Verma, Vivek, et al.
Publicado: (2016)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
por: Dahlgren, David, et al.
Publicado: (2020)

Current Status: Site-Specific Antibody Drug Conjugates
por: Schumacher, Dominik, et al.
Publicado: (2016)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tp214hs09613d1r8kgfa5movs4